Related Experiment Video
Updated: Apr 12, 2026

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
Astrocytic calcium-dependent enzyme PAD2 governs microglia activity to exacerbate amyloid pathology via citrullinated
Jingyan Zhang1, Yufei Huang1, Yanbing Chen1
1Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou 350001, China.
Abstract:
Glial crosstalk surrounding amyloid-β (Aβ) plaques establishes a self-propagating inflammatory niche fueling Alzheimer's disease (AD), yet the molecular triggers remain incompletely defined. We found that the calcium-dependent enzyme peptidyl-arginine deiminase 2 (PAD2) was selectively upregulated in plaque-associated astrocytes in human AD cortex and multiple APP AD transgenic mouse models. Astrocyte-specific deletion of Padi2 in 5×FAD mice rescued learning and memory, lowered Aβ load, restrained pro-inflammatory microglial activation, and restored microglial phagocytosis. Multi-omics profiling tied these benefits to rewiring of the astrocytic proteome and the microglial transcriptome toward homeostasis. PAD2 converted astrocytic vimentin to citrullinated Cit-Vim175/184. The released Cit-vimentin drove a proinflammatory phenotype while dampening Aβ clearance in microglia-a process dependent on TLR4 signaling. Pharmacological PAD2 inhibition mimicked the genetic rescue, normalizing glial signatures and cognition. These findings identify PAD2-dependent vimentin citrullination as a key inter-glial signaling hub that worsens AD pathology and highlight PAD2 as a promising therapeutic target.
Insights
Researchers discovered that the enzyme peptidyl-arginine deiminase 2 (PAD2) drives Alzheimer's disease (AD) inflammation by altering astrocyte proteins. Inhibiting PAD2 improved cognition and reduced AD pathology in mouse models.
Area of Science:
- Neuroscience
- Molecular Biology
- Immunology
Background:
- Glial cells (astrocytes and microglia) form a pro-inflammatory environment around amyloid-β (Aβ) plaques, contributing to Alzheimer's disease (AD) progression.
- The precise molecular mechanisms initiating this detrimental glial crosstalk are not fully understood.
Purpose of the Study:
- To investigate the role of peptidyl-arginine deiminase 2 (PAD2) in AD pathogenesis.
- To identify PAD2 as a potential therapeutic target for AD.
Main Methods:
- Examined PAD2 expression in human AD brain tissue and APP AD transgenic mouse models.
- Utilized astrocyte-specific Padi2 gene deletion in 5×FAD mice.
- Performed multi-omics profiling (proteomics and transcriptomics).
- Investigated the effect of PAD2 inhibition on glial cells and AD pathology.
Main Results:
- PAD2 was upregulated in astrocytes near Aβ plaques in human AD cortex and mouse models.
- Astrocyte-specific deletion of Padi2 in 5×FAD mice improved learning/memory, reduced Aβ load, and restored microglial phagocytosis.
- PAD2 citrullinated vimentin in astrocytes, generating Cit-Vim175/184, which promoted inflammation and impaired microglial Aβ clearance via TLR4 signaling.
- Pharmacological PAD2 inhibition replicated genetic rescue effects, normalizing glial function and cognition.
Conclusions:
- PAD2-mediated vimentin citrullination acts as a critical inter-glial signaling pathway exacerbating AD pathology.
- Targeting PAD2 offers a promising therapeutic strategy for Alzheimer's disease.
More Related Videos
09:12Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Ligand-Gated Ion Channel Receptor: Gating Mechanism